Authors’ Disclosures
Cancer, Pierre, Leukemia, fromAstraZeneca, P., Schönborn-Kellenberger, Oncology/Cancer
ONCOLOGY, LEUKEMIA, CANCER
G. J. Hanna reports relevant consulting/advisory for Kura, Prelude, and Remix; research support to institution from AACRF, Actuate, Elevar, Gateway for Cancer Research, Genentech, Immunitybio, and V Foundation. A. Stathis reports other, institutional, travel grant from AstraZeneca, Incyte; expert testimony, institutional from Eli Lilly and Bayer; advisory board, institutional from Janssen and Roche; local PI, institutional, financial interest from Abbvie, ADC Therapeutics, Amgen, Bayer, Cellestia, Loxo Oncology, Merck MSD, Novartis, Pfizer, Philogen, Roche; trial chair, institutional, financial interest from AstraZeneca, Incyte. E. Lopez-Miranda reports consultant/advisory board role in AstraZeneca, Daiichi Sankyo, Novartis, Roche and has received travel, inscription, and accommodation funding from Roche and Seagen. F. Racca reports speakers bureau from Roche and Bristol-Myers Squibb; travel, accommodation and expenses Roche, Bristol-Myers Squibb, Merck Sharp & Dohme; consulting and advisory role: Bristol-Myers Squibb; expert testimony: Pharmore research, Psyma. S. Leyvraz reports support for congress and travel from Bayer. D. Hess reports to be shareholder of the following pharmaceutical companies: Roche, Novartis, and Bayer. B. Keam reports honoraria from Merck, Yuhan, Lilly; consulting/advisory from Handok, CBS Bioscience, Trial Informatics, NeoImmuneTech, ImmuneOncia; research funding: Ono Pharmaceutical, MSD Oncology, AstraZeneca. J. Rodon reports non-financial support and reasonable reimbursement for travel from European Society for Medical Oncology; receiving consulting and travel fees from Peptomyc, Kelun Pharmaceuticals/Klus Pharma, Ellipses Pharma, Molecular Partners, IONCTURA (including serving on the scientific advisory board); consulting fees from Vall d'Hebron Institute of Oncology/Ministero De Empleo Y Seguridad Social, Chinese University of Hong Kong, Boxer Capital, LLC, Tang Advisors, LLC receiving research funding from Blueprint Medicines, Black Diamond Therapeutics, Merck Sharp & Dohme, Hummingbird, Yingli and Vall d'Hebron Institute of Oncology/Cancer Core Europe; and serving as investigator in clinical trials with Novartis, Spectrum Pharmaceuticals, Symphogen, BioAlta, Pfizer, GenMab, CytomX, Kelun-Biotech, Takeda-Millenium, GalxoSmithKline, Taiho, Roche Pharmaceuticals, Hummingbird, Yingli, Bicycle Therapeutics, Merus, Curis, Bayer, AadiBioscience, Nuvation, ForeBio, BioMed Valley Discoveries, Loxo Oncology, Hutchinson MediPharma, Cellestia, Deciphera, Ideaya, Amgen, Tango Therapeutics, Mirati Linnaeus Therapeutics, and Cancer Core Europe. M.J. Ahn reports honoraria fromAstraZeneca, BMS, MSD, Lilly, Merck, Ono, Roche, Takeda, Yuhan, Amgen and consultant or Advisor for AstraZeneca, BMS, ONO, Takeda, Lilly, Merck, MSD, Amgen, Novartis, Roche, Yuhan, Arcus, Pfizer, Daichi-Sankyo, Alpha Pharmaceutical, Boronoi. A. Schneeweiss reports grants from Celgene, Roche, AbbVie; personal fees from Celgene, Roche, Pfizer, AstraZeneca, Novartis, MSD, Tesaro, Lilly, Seagen, Gilead, GSK, Bayer, Amgen, Pierre Fabre. J.-M. Ribera reports speaker and advisory boards honoraria, clinical trials from Ariad and Pfizer; speaker and advisory boards honoraria, research support, clinical trials from Amgen; speaker and advisory boards honoraria from Shire. D. Deangelo serves as a consultant for Autolos, Blueprint, Gilead, Incyte, Jazz, Kite, Novartis, Pfizer, Servier, and Takeda; receives research funding from Abbvie, Glycomimetics, Novartis, and Blueprint Pharmaceuticals; serves on the DSMB for Daiichi-Sankyo, Fibrogen, and Mt Sinai MPN Consortium; and is the co-chair of the NCI (CTEP) Leukemia Steering Committee. J.M. Perez Garcia reports advisory role from Lilly, Roche, Eisai, Daichii Sankyo, Seattle Genetics, Gilead; travel expenses from Roche. J. Cortes reports consulting/advisor to Roche, Celgene, Cellestia, AstraZeneca, Seattle Genetics, Daiichi Sankyo, Erytech, Athenex, Polyphor, Lilly, Merck Sharp&Dohme, GSK, Leuko, Bioasis, Clovis Oncology, Boehringer Ingelheim, Ellipses, Hibercell, BioInvent, Gemoab, Gilead, Menarini, Zymeworks, Reveal Genomics, Expres2ion Biotechnologies; honoraria from Roche, Novartis, Celgene, Eisai, Pfizer, Samsung Bioepis, Lilly, Merck Sharp&Dohme, Daiichi Sankyo, AstraZeneca; research funding to the Institution from Roche, Ariad pharmaceuticals, AstraZeneca, Baxalta GMBH/Servier Affaires, Bayer Healthcare, Eisai, F.Hoffman-La Roche, Guardanth health, Merck Sharp&Dohme, Pfizer, Piqur Therapeutics, Puma C, Queen Mary University of London. Stock: MedSIR, Nektar Pharmaceuticals, Leuko (relative); travel, accommodation, expenses from Roche, Novartis, Eisai, pfizer, Daiichi Sankyo, AstraZeneca, Gilead, Merck Sharp&Dhome. O. Schönborn-Kellenberger is a Cellestia Biotech AG consultant. D. Weber is a Cellestia Biotech AG shareholder. P. Pisa is a Cellestia Biotech AG shareholder. M. Bauer is a Cellestia Biotech AG shareholder. L. Beni is a Cellestia Biotech AG shareholder. M. Bobadilla is a Cellestia Biotech AG employee. R. Lehal is a Cellestia Biotech AG employee. M. Vigolo is a Cellestia Biotech AG employee. F.D. Vogl is a Cellestia Biotech AG employee. E. Garralda reports research support from Novartis, Roche, Thermo Fisher Scientific, AstraZeneca, Taiho, BeiGene, Janssen; consultant/advisor for Roche, Ellipses Pharma, Boehringer Ingelheim, Janssen Global Services, Seattle Genetics, Alkermes, Thermo Fisher Scientific, MabDiscovery, Anaveon, F-Star Therapeutics, Hengrui, Sanofi, Incyte; speakers bureau: Merck Sharp & Dohme, Roche, Thermo Fisher Scientific, Lilly, Novartis, SeaGen; employment: NEXT Oncology. No disclosures were reported by other authors.